



## Monaldi Archives for Chest Disease

eISSN 2532-5264

<https://www.monaldi-archives.org/>

**Publisher's Disclaimer.** E-publishing ahead of print is increasingly important for the rapid dissemination of science. The **Early Access** service lets users access peer-reviewed articles well before print / regular issue publication, significantly reducing the time it takes for critical findings to reach the research community.

These articles are searchable and citable by their DOI (Digital Object Identifier).

The **Monaldi Archives for Chest Disease** is, therefore, e-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear in a regular issue of the journal.

E-publishing of this PDF file has been approved by the authors.

*All legal disclaimers applicable to the journal apply to this production process as well.*

Monaldi Arch Chest Dis 2023 [Online ahead of print]

*To cite this Article:*

Alamri F, Eltayeb A, Hamad A, et al. **A native mitral valve mass beyond imagination.**  
*Monaldi Arch Chest Dis* doi: 10.4081/monaldi.2023.2649



©The Author(s), 2023  
Licensee [PAGEpress](#), Italy

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.



## **A native mitral valve mass beyond imagination**

Faisal Alamri,<sup>1</sup> Abdalla Eltayeb,<sup>1</sup> Alaa Hamad,<sup>2</sup> Soaad Alamri,<sup>2</sup> Sultan Alamri,<sup>3</sup> Wassima Kaidali,<sup>2</sup> Loay Tashkandi,<sup>2</sup> Lana Arbili,<sup>2</sup> Valeria Pergola,<sup>4</sup> Hani Al Sergani<sup>1</sup>

<sup>1</sup>The Heart Centre, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia

<sup>2</sup>College of Medicine, Alfaisal University, Riyadh, Saudi Arabia

<sup>3</sup>King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

<sup>4</sup>Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Italy

**Corresponding author:** Abdalla Eltayeb, The Heart Centre, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia. E-mail: [abdullaheltayeb2002@gmail.com](mailto:abdullaheltayeb2002@gmail.com)

**Acknowledgments:** We would like to thank Fatima Arshi, RCS, for the master collaboration in performing the studies and in analyzing and reviewing the images.

### **Authors' contributions**

All authors contributed equally to writing and reviewing the manuscript.

Faisal Alamri: performing operation and interpretation of imaging

Abdallah Eltayeb: collection and interpretation of imaging, manuscript and figures drafting, clinical decision making of the patients

Alaa Hamad: data collection, manuscript writing, and figures drafting

Soaad Alamri: data collection, manuscript writing, and figures drafting

Sultan Alamri: data collection, manuscript writing, and figures drafting

Wassima Kaidali: data collection, manuscript writing, and figures drafting

Loay Tashkandi: data collection, manuscript writing, and figures drafting

Lana Arbili: data collection, manuscript writing, and figures drafting

Valeria Pergola: collection and interpretation of imaging

Hani Al Sergani: collection and interpretation of imaging, clinical decision making of the patients

All the authors have read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work

**Availability of data and materials:** All data underlying the findings are fully available.

**Ethics approval and consent to participate:** Waived ethical committee approval. Informed consent was obtained from the patient included in this study.

**Funding:** No funding was obtained for this study.

**Conflicts of interests:** No conflicts of interest were declared by the authors.

**Informed consent:** obtained from a legally authorized representative for anonymized patient information to be published in this article.

## **Abstract**

The authors report a case of a patient with a history of IgA nephropathy that, during the admission for pneumonia, was found to have an incidental finding of a huge mitral valve (MV) mass on transthoracic echocardiography. The differential diagnosis was challenging because the clinical scenario raised the suspicion of possible infective endocarditis and the imaging features were suggestive of a myxoma or vegetation. The patient underwent urgent excision of the mass with MV replacement due to the high risk of embolism. Intraoperative findings were consistent with clot or vegetation. Pathology result of thrombus was beyond our imagination and at the best of our knowledge one case only has been reported. Awareness about native MV thrombosis and its etiologic factors, workup, and management is key for better medical and surgical management planning because this condition is extremely rare and challenging in the clinical and imaging arena.

**Keywords:** native mitral valve thrombosis; echocardiography; intracardiac mass; hypercoagulable state.

## **Case Report**

A year prior to admission, a 32-year-old male with a history of hypertension experienced shortness of breath (SOB), hemoptysis, and lower limb edema after receiving the COVID vaccine. He was hospitalized and diagnosed with acute kidney injury due to IgA nephropathy, confirmed by renal biopsy. The patient did not have a history of

tuberculosis or intravenous drug use but had a family history of systemic lupus erythematosus (SLE).

One month before his admission to our hospital, the patient sought treatment at a local hospital for new-onset SOB, chest pain, and hemoptysis lasting 2 weeks. He was diagnosed with pneumonia and treated with antibiotics. During routine transthoracic echocardiography (TTE), a mass on the mitral valve was discovered, prompting referral to our hospital. The patient's work-up showed an electrocardiogram (ECG) of normal sinus rhythm, elevated creatinine levels (321  $\mu\text{mol/L}$ ), normal complete blood counts (CBC), and negative blood cultures. Immunological tests revealed an increased erythrocyte sedimentation rate (ESR), as well as positive anti-cardiolipin antibodies. Coagulation profile tests indicate a D-dimer measurement of 0.58  $\mu\text{g/ml}$ , fibrinogen levels of 8.2  $\text{g/L}$  (elevated), a PTT reading of 89 seconds (elevated), and a normal INR. Testing for Goodpasture syndrome was negative. TTE showed a multilobulated, large, raceme-shaped, mobile mass protruding in diastole into the left ventricle (LV) with irregular borders. It was a non-homogeneous mainly myocardial-like texture with focal areas of hyperechogenicity (size 19 x 19 mm), likely attached by a broad peduncle on the atrial side of the basal mid portion of the anterior mitral leaflet (AML) (Figure 1). The mitral valve (MV) leaflets were thickened with focal areas of calcification. There was an eccentric systolic jet directed toward the posterolateral atrial wall due to the AML impaired mobility (mass-related) causing incomplete coaptation of the leaflets and severe mitral regurgitation (MR). The LV was normal in size and function. A contrast TTE study using Optison infusion was performed in order to detect the blood supply of the mass and it showed no early or 20 min delayed uptake into the mass (Figure 1).

Further two and three-dimensional (3D) transesophageal echocardiography (TEE) allowed a better visualization and sizing of the mass (found larger than in TTE, size 3.2 x 1.1 cm). TEE confirmed the sessile attachment to the base/mid portion of the atrial surface of the AML. TEE 2D and 3D allowed us to better delineate the morphologic features of the mass (site and type of attachment, texture, shape) (Figure 2).

The case was discussed in the multi-disciplinary team (MDT) meeting. According to the clinical and the imaging pattern, it was decided to proceed with emergent surgery due to the high risk of embolism even without further imaging workup by magnetic resonance

imaging (MRI). The patient was maintained on heparin infusion till the time of the surgery. No change in size was detected during the preoperative TEE.

At Surgery MV repair was not possible (due to the calcifications of the leaflets) and the mass was impossible to resect as it was strongly attached without damaging the leaflets). Therefore, the MV was replaced. We found a red, mushy tissue between the gelatinous and firm tissue and with an irregular surface. Its size was about 3.4 cm. The mass was attached to the atrial surface anterior mitral leaflet (Figure 3).

The surgeon's impression of the anatomical features of the lesion (consistency, color, surface) was of vegetation or clot. The patient had an uneventful surgical course and was discharged home with stable condition. After immunohistochemistry and histological analysis of the mass, it is found to be a thrombus.

## **Discussion**

Without rheumatic heart disease or thrombophilic disease, native mitral valve (MV) leaflet thrombosis is extremely rare and at the best of our knowledge one case only has been reported. Prior cases of native valve thrombi have been associated with antiphospholipid syndrome, hypercoagulable states, hypereosinophilic syndrome, and rheumatic mitral valves [1-6]. They more often involve prosthetic valves with an incidence of 1% to 3% per year [7-9]. We report a rare clinical case of a patient with a history of IgA nephropathy, pneumonia, and a huge mass on the native mitral valve. The diagnosis was challenging because the clinical scenario raised the suspicion of possible infective endocarditis [7] while the patient was found to have a MV mass during concomitant pneumonia and the imaging features were suggestive of a myxoma or vegetation [10-15] being the mass huge in size, raceme shaped and attached on a leaflet with normal mobility therefore unlikely site of origin of a large clot in particular without history of known thrombophilic disease. The possibility of remnants of healed vegetation was also unlikely due to the size of the mass. Our MDT meeting consensus was that the very high risk of embolism required proceeding with emergent surgery without any further MRI imaging and laboratory workup. However, we have to highlight that, in the intracardiac masses imaging pathway, MRI has a key role. Even though contrast echocardiography did not show any early or late uptake therefore suggesting a structure without blood supply [10], this finding was believed suggestive of vegetation more than

clot. The intraoperative findings were consistent with either vegetation or clot (appearance, color, consistency, and adherence). Pathological and histochemical evaluation of the mass and the leaflets unexpectedly found the mass to be a clot with no findings of infective endocarditis or cellular transformation. Clot had not been considered because thrombosis rarely occurs on native valves. In the intracardiac masses imaging pathway, echocardiography represents the first diagnostic technique able to diagnose the presence of an intracardiac mass and visualize the anatomical features of the lesion [10-12]. In the imaging arena, three-dimensional (3D) transesophageal (TEE) can have an important adjunctive value, as it is better able to demonstrate many anatomical features and in particular the type and site of attachment of pedunculated cardiac tumors [10-15]. In our case, 3D TEE was able to provide the best visualization of the attachment. Cardiac magnetic resonance has a key role in the diagnosis of cardiac mass and is now a highly effective powerful tool due to its soft tissue characterization sequences, including fat saturation, water content, blood perfusion, vascularity of the mass, as well as anatomical features including attachment and size [13].

Prior cases of native valve thrombi have been associated with antiphospholipid syndrome, hypercoagulable states, hypereosinophilic syndrome, and rheumatic mitral valves [1-7]. Only one case of thrombosis on a native non-rheumatic MV has been reported [1].

It has been reported that patients with chronic kidney disease (CKD) manifest a coagulopathy consisting of delayed clot formation but increased final clot strength and decreased clot breakdown [15,16]. The increased clot strength is mediated by elevated fibrinogen levels in CKD. The findings of delayed clot formation, decreased lysis, and increased fibrinogen levels have been reported in previous studies. While The delayed clot formation seen may predispose to bleeding complications, on the other hand, the increased clot strength and decreased breakdown in this group may account for the increased thrombotic complications in this group. Thus, methods to treat hypercoagulability in this population should also consider targeting fibrinogen [13,16,17].

In our case, the pt was affected by IgA nephropathy, the coagulation profile showed positive D-dimer of 0.58 ug/mL, increased fibrinogen level at 8.2 g/L, 89 seconds PTT, anti-cardiolipin antibodies were positive supporting the presence of a hypercoagulable

state. However, it is very unclear the pathogenetic mechanism of the formation of a huge clot on the native mitral valve leaflet. In fact, in our case there was no atrio-ventricular low-flow status that is present in condition like rheumatic valvulopathies, arrhythmias or reduced left ventricular function that can predispose to the formation of large clot [18]. We speculated as a possible pathogenetic pathway a clot formation on a damaged, inflamed leaflet surface due to a possible valvulitis either by infective endocarditis or immunological phenomena on a degenerative leaflet because of CKD (in fact the MV leaflet were thickened and with extensive calcification) in a patient that has a hypercoagulable state due to a post covid vaccine IgA nephropathy.

While one case had been reported on MV, thrombosis on native aortic valve even uncommon is relatively more frequent. On a recent meta-analysis, 74 cases of aortic valve thrombosis had been reported. The most common underlying etiologies were hypercoagulable diseases (30%), idiopathic (19%), left ventricular assist devices (18%), aortic valve or root disease (17%), and congenital heart disease (8%). This condition appeared to be associated with an increased risk for in-hospital poor outcomes. Therefore, aortic valve thrombosis is more clinically relevant in patients with embolic events [19].

The scenario of clot on native MV can also widen the horizon towards different therapeutic strategies by thrombolysis that was not considered in our clinical scenario, different modalities of anticoagulation, surgical timing, and, when surgical resection is believed necessary for the high risk of embolism, the repair of the valve the best option. However, in our case urgent surgery due to the very high risk of embolism in the setting of possible infective endocarditis in a young male was considered the best therapeutical choice [7], and the repair was not feasible due to the degenerative MV and the size and anatomical features of the mass.

## **Conclusions**

Awareness about native MV thrombosis and its etiologic factors, diagnostic work-up, and management is paramount for better medical and surgical management planning because this condition is extremely rare and challenging in the clinical and imaging arena and can be associated with a poor outcome.

## References

1. Howell SJ, Datta Mitra A, Amsterdam EA. What's in a mass? Large native mitral valve mass. *Am J Med* 2017;130:e171-5.
2. Karnib M, Helmy I, Annam A, et al. Thrombosis of native rheumatic mitral valve: A case report. *Echocardiography* 2022;39:390-7.
3. Güllülü S, Kaderli AA, Ozdemir B. Mitral valve thrombosis and infective endocarditis in a patient with prothrombin mutation. *Acta Cardiol* 2006;61:673-5.
4. Elmistekawy E, Chan V, Lambert AS, Mesana T. An unusual case of native mitral valve thrombosis and obstruction. *Eur J Cardiothorac Surg* 2015;48:971.
5. Zakhama L, Slama I, Boussabah E, et al. Recurrent native and prosthetic mitral valve thrombosis in idiopathic hypereosinophilic syndrome. *J Heart Valve Dis* 2014;23:168-70.
6. Endara SA, Dávalos GA, Fierro CH, et al. Antiphospholipid syndrome and valvular heart disease, a complex scenario of thrombotic events, a case report. *J Cardiothorac Surg* 2020;15:275.
7. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Rev Esp Cardiol (Engl Ed)* 2022;75:524.
8. Renzulli A, De Luca L, Caruso A, et al. Acute thrombosis of prosthetic valves: a multivariate analysis of the risk factors for a lifethreatening event. *Eur J Cardiothorac Surg* 1992;6:412-21.
9. Vríz O, Rossi Zadra A, Eltayeb A, et al. Loss of engagement in controlling chronic anticoagulation therapy during Covid-19 stringency measures. A single center experience of disproportioned increase of stuck mechanical valves. *Monaldi Arch Chest Dis* 2021;92:2065.
10. Mankad R, Herrmann J. Cardiac tumors: echo assessment. *Echo Res Pract* 2016;3:R65:77.
11. Parato VM, Nocco S, Alunni G, et al. Imaging of cardiac masses: an updated overview. *J Cardiovasc Echogr* 2022;32:65-75.
12. Galzerano D, Pragliola C, Al Admawi M, et al. The role of 3D echocardiographic imaging in the differential diagnosis of an atypical left atrial myxoma. *Monaldi Arch Chest Dis* 2018;88:906.
13. Galzerano D, Pergola V, Kinsara AJ, et al. Right-sided infective endocarditis and pulmonary embolism: A multicenter study. *Monaldi Arch Chest Dis* 2022;92:2251.
14. Galzerano D, Kinsara AJ, Di Michele S, et al. Three dimensional echocardiography: a missing link in infective endocarditis imaging. *Int J Cardiovasc Imaging* 2020;36:403-13.



15. Gatti M, D'Angelo T, Muscogiuri G, et al. Cardiovascular magnetic resonance of cardiac tumors and masses. *World J Cardiol* 2021;13:628-49.
16. Nunns GR, Moore EE, Chapman MP, et al. The hypercoagulability paradox of chronic kidney disease: The role of fibrinogen. *Am J Surg* 2017;214:1215-8.
17. Lutz J, Menke J, Sollinger D, et al. Haemostasis in chronic kidney disease. *Nephrol Dial Transplant* 2014;29:29-40.
18. Selimi A, Ianni U, Molisana M, Parato VM. A giant and double-walled left atrial ball thrombus complicating a mitral stenosis: case report - a truck tire into the heart. *Eur Hear J Case Rep* 2022;6:ytac443.
19. Alajaji W, Hornick JM, Malek E, Klein AL. The characteristics and outcomes of native aortic valve thrombosis: a systematic review. *J Am Coll Cardiol* 2021;78:811-24.





Figure 1. Trans-thoracic echocardiography. A) Parasternal long axis view (PLAX) at mid-systole showing the mass attached to AML. B) PLAX), systole, color doppler at mitral valve showing posteriorly directed jet of MR. C,D) Baseline contrast-enhanced echocardiography by Optison showing left ventricular opacification and no uptake of contrast the mass (baseline) (C) and 20 min after the contrast (D). LV, left ventricle; LA, left atrium; RV, right ventricle.






Figure 3. Surgical specimen. A) Specimen of the AML, ventricular surface. B) AML atrial side calcified nodule (yellow arrow); C) Red, mushy tissue between the gelatinous and firm tissue, irregular surface size 3.4 cm mass (thrombus).